Beta Drugs Statistics

Total Valuation

Beta Drugs has a market cap or net worth of INR 11.08 billion. The enterprise value is 11.32 billion.

Market Cap	11.08B
Enterprise Value	11.32B

Important Dates

The last earnings date was Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Beta Drugs has 10.09 million shares outstanding. The number of shares has increased by 10.48% in one year.

Current Share Class	10.09M
Shares Outstanding	10.09M
Shares Change (YoY)	+10.48%
Shares Change (QoQ)	+100.87%
Owned by Insiders (%)	1.05%
Owned by Institutions (%)	n/a
Float	3.36M

Valuation Ratios

The trailing PE ratio is 27.77.

PE Ratio	27.77
Forward PE	n/a
PS Ratio	2.88
PB Ratio	5.02
P/TBV Ratio	5.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	27.29
EV / Sales	2.94
EV / EBITDA	15.25
EV / EBIT	19.04
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.66
Debt / EBITDA	1.96
Debt / FCF	n/a
Interest Coverage	4.13

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	18.42%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	2.21%
Revenue Per Employee	9.64M
Profits Per Employee	1.04M
Employee Count	399
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Beta Drugs has paid 133.27 million in taxes.

Income Tax	133.27M
Effective Tax Rate	24.32%

Stock Price Statistics

The stock price has decreased by -35.16% in the last 52 weeks. The beta is -0.50, so Beta Drugs's price volatility has been lower than the market average.

Beta (5Y)	-0.50
52-Week Price Change	-35.16%
50-Day Moving Average	1,390.59
200-Day Moving Average	1,674.20
Relative Strength Index (RSI)	33.05
Average Volume (20 Days)	19,234

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beta Drugs had revenue of INR 3.85 billion and earned 414.68 million in profits. Earnings per share was 39.54.

Revenue	3.85B
Gross Profit	1.65B
Operating Income	594.22M
Pretax Income	547.95M
Net Income	414.68M
EBITDA	741.83M
EBIT	594.22M
Earnings Per Share (EPS)	39.54

Full Income Statement

Balance Sheet

The company has 1.23 billion in cash and 1.46 billion in debt, giving a net cash position of -231.88 million or -22.97 per share.

Cash & Cash Equivalents	1.23B
Total Debt	1.46B
Net Cash	-231.88M
Net Cash Per Share	-22.97
Equity (Book Value)	2.21B
Book Value Per Share	437.84
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 42.78%, with operating and profit margins of 15.45% and 10.78%.

Gross Margin	42.78%
Operating Margin	15.45%
Pretax Margin	14.25%
Profit Margin	10.78%
EBITDA Margin	19.29%
EBIT Margin	15.45%
FCF Margin	n/a

Dividends & Yields

Beta Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.48%
Shareholder Yield	-10.48%
Earnings Yield	3.74%
FCF Yield	n/a

Stock Splits

The last stock split was on March 26, 2025. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 26, 2025
Split Type	Forward
Split Ratio	1.05

Scores

Altman Z-Score	n/a
Piotroski F-Score	1